| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
66,230,000 |
| Market
Cap: |
4.11(M) |
| Last
Volume: |
362,100 |
Avg
Vol: |
361,089 |
| 52
Week Range: |
$0.062 - $0.062 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sidransky David |
Director |
– • – |
2018-06-13 |
4 |
A |
$1.71 |
$8,550 |
D/D |
5,000 |
95,355 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2018-06-12 |
4 |
A |
$1.84 |
$9,200 |
D/D |
5,000 |
231,639 |
|
- |
|
| Patton James P |
Director |
– • – |
2018-06-12 |
4 |
A |
$1.84 |
$92,000 |
D/D |
50,000 |
261,749 |
|
- |
|
| Henderson Molly |
Executive Vice President & CFO |
• – – |
2018-06-12 |
4 |
A |
$1.89 |
$9,450 |
D/D |
5,000 |
5,000 |
|
- |
|
| Sidransky David |
Director |
– • – |
2018-06-12 |
4 |
A |
$1.84 |
$18,432 |
D/D |
10,000 |
90,355 |
|
- |
|
| Berlin Kenneth A |
President & CEO |
• • – |
2018-06-12 |
4 |
A |
$1.84 |
$27,600 |
D/D |
15,000 |
265,000 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2018-05-31 |
4 |
A |
$1.82 |
$3,212 |
D/D |
1,765 |
226,639 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2018-04-30 |
4 |
A |
$1.60 |
$2,198 |
D/D |
1,374 |
224,874 |
|
- |
|
| Berlin Kenneth A |
President & CEO |
• • – |
2018-04-23 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
250,000 |
|
- |
|
| Lombardo Anthony A |
Interim CEO |
• – – |
2018-04-17 |
4 |
D |
$1.70 |
$18,787 |
D/D |
(11,051) |
81,852 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2018-04-02 |
4 |
S |
$1.62 |
$3,553 |
D/D |
(2,193) |
223,500 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2018-03-29 |
4 |
A |
$1.69 |
$1,839 |
D/D |
1,088 |
226,670 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2018-03-29 |
4 |
A |
$1.69 |
$1,878 |
D/D |
1,111 |
225,693 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2018-02-28 |
4 |
A |
$1.86 |
$2,199 |
D/D |
1,182 |
224,582 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2018-02-28 |
4 |
A |
$1.86 |
$1,840 |
D/D |
989 |
225,582 |
|
- |
|
| Lombardo Anthony A |
Interim CEO |
• – – |
2018-02-02 |
4 |
S |
$2.93 |
$94 |
D/D |
(32) |
92,903 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2018-01-31 |
4 |
A |
$2.96 |
$2,060 |
D/D |
696 |
223,400 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2018-01-31 |
4 |
A |
$2.96 |
$1,717 |
D/D |
580 |
224,593 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2018-01-03 |
4 |
S |
$3.18 |
$16,612 |
D/D |
(5,224) |
224,013 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2017-12-29 |
4 |
A |
$2.84 |
$1,343 |
D/D |
473 |
229,237 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2017-12-29 |
4 |
A |
$2.84 |
$2,136 |
D/D |
752 |
222,704 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2017-11-30 |
4 |
A |
$2.99 |
$2,559 |
D/D |
856 |
228,764 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2017-11-30 |
4 |
A |
$2.99 |
$3,095 |
D/D |
1,035 |
221,952 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2017-11-06 |
4 |
S |
$3.30 |
$12,286 |
D/D |
(3,723) |
220,917 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2017-11-06 |
4 |
S |
$3.30 |
$12,745 |
D/D |
(3,862) |
227,908 |
|
- |
|
465 Records found
|
|
Page 2 of 19 |
|
|
